Sylvine Coutisson

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort

Catherine Hewison, Uzma Khan, Mathieu Bastard et al. · Clinical Infectious Diseases · 2022 · 53 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India

Mrinalini Das, Alpa Dalal, Chinmay Laxmeshwar et al. · Clinical Infectious Diseases · 2020 · 28 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Lorenzo Guglielmetti, Uzma Khan, Gustavo E. Velásquez et al. · The Lancet Respiratory Medicine · 2025 · 24 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

Ismat Lotia‐Farrukh, Nathalie Lachenal, Malik M Adenov et al. · Clinical Infectious Diseases · 2023 · 16 citations · Full text

Public Health, Maternal Health, Obstetrics +17

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Shrikant Patil, Meseret Tamirat, K S Khazhidinov et al. · Trials · 2023 · 13 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13